Sun Pharma on Monday said it has entered into a global licensing agreement for commercializing Swiss-Italian biotech Philogen ’s specialty anti-cancer immunotherapy Fibromun (L19TNF). Fibromun is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma (malignant forms of brain tumors). Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun.
Philogen will complete the ongoing pivotal clinical trials for the product, pursue marketing authorization with regulatory authorities, and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two companies will share post-commercialization economics in about 45(Philogen):55(Sun Pharma) ratio.
Other financial terms were not disclosed. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Basics of Generative AI : Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Master in.
